404 results on '"Heath, K."'
Search Results
2. Biochemical algorithm to identify individuals with ALPL variants among subjects with persistent hypophosphatasaemia
- Author
-
Tornero, C., Navarro-Compán, V., Buño, A., Heath, K. E., Díaz-Almirón, M., Balsa, A., Tenorio, J. A., Quer, J., and Aguado, P.
- Published
- 2022
- Full Text
- View/download PDF
3. Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation
- Author
-
Fernández-Sánchez, M. E., Criado-García, O., Heath, K. E., García-Fojeda García-Valdecasas, María Belén, Medraño-Fernández, Iria, Gómez-Garre, Pilar, Sanz, Pascual, Serratosa, José María, Rodríguez de Córdoba, Santiago, Fernández-Sánchez, M. E., Criado-García, O., Heath, K. E., García-Fojeda García-Valdecasas, María Belén, Medraño-Fernández, Iria, Gómez-Garre, Pilar, Sanz, Pascual, Serratosa, José María, and Rodríguez de Córdoba, Santiago
- Abstract
Progressive myoclonus epilepsy of Lafora type (LD, MIM 254780) is a fatal autosomal recessive disorder characterized by the presence of progressive neurological deterioration, myoclonus, epilepsy and polyglucosan intracellular inclusion bodies, called Lafora bodies. Lafora bodies resemble glycogen with reduced branching, suggesting an alteration in glycogen metabolism. Linkage analysis and homozygosity mapping localized EPM2A, a major gene for LD, to chromosome 6q24. EPM2A encodes a protein of 331 amino acids (named laforin) with two domains, a dual-specificity phosphatase domain and a carbohydrate binding domain. Here we show that, in addition, laforin interacts with itself and with the glycogen targeting regulatory subunit R5 of protein phosphatase 1 (PP1). R5 is the human homolog of the murine Protein Targeting to Glycogen, a protein that also acts as a molecular scaffold assembling PP1 with its substrate, glycogen synthase, at the intracellular glycogen particles. The laforin–R5 interaction was confirmed by pull-down and co-localization experiments. Full-length laforin is required for the interaction. However, a minimal central region of R5 (amino acids 116–238), including the binding sites for glycogen and for glycogen synthase, is sufficient to interact with laforin. Point-mutagenesis of the glycogen synthase-binding site completely blocked the interaction with laforin. The majority of the EPM2A missense mutations found in LD patients result in lack of phosphatase activity, absence of binding to glycogen and lack of interaction with R5. Interestingly, we have found that the LD-associated EPM2A missense mutation G240S has no effect on the phosphatase or glycogen binding activities of laforin but disrupts the interaction with R5, suggesting that binding to R5 is critical for the laforin function. These results place laforin in the context of a multiprotein complex associated with intracellular glycogen particles, reinforcing the concept that laforin is involved, Ministerio de Ciencia y Tecnología, Instituto de Salud Carlos III, Asociación Lafora España, Depto. de Bioquímica y Biología Molecular, Fac. de Ciencias Químicas, TRUE, pub
- Published
- 2024
4. The effects of the circadian clock on wound healing in skin
- Author
-
Heath, K. S. C.
- Subjects
570 - Abstract
Circadian rhythms are daily cycles of physiological functions which oscillate under the control of the circadian clock in order to coincide with the temporal demands of the light/dark cycle of the day. The importance of the integrity of the circadian clock in health and disease has emerged in recent years; perturbations of the circadian clock are associated with an increased risk of malignancy and metabolic syndrome. In this study, I aimed to examine whether RNAi modification of Bmal1, a core component of the circadian clock, could be used to improve wound healing. Chronic wounds are a global problem, in part caused by diabetes and ageing. Currently there is no effective pharmaceutical treatment; wound care by specialist nurses and physical methods such as compression bandages are the main course of action. Originally, the aim was to use DNA antisense to transiently knock down Bmal1. It became clear that this was having a toxic effect so several other approaches to knocking down Bmal1 expression were attempted. Ultimately, I used a lentiviral vector to transduce cells with an shRNA construct and also generated a Bmal1:luciferase reporter cell line to measure the oscillations of Bmal1 in vitro. Experiments using the reporter cells demonstrated that commonly used methods to synchronise the circadian clock in mammalian cells confirmed that these measures are unnecessary. The generation of cells with Bmal1 knockdown was only partially successful; however, an experiment using a heterogeneous population of Bmal1 knockdown cells indicates that this intervention reduces the migration rate of these cells in a scratch wound assay but further experiments are required to definitively determine the effects once a stable knockdown cell line has been established. If these preliminary results are true then the knockdown of Bmal1 is not likely to have a beneficial effect on wound healing.
- Published
- 2016
5. Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C
- Author
-
Heath K
- Subjects
ledipasvir ,sofosbuvir ,cost-per-QALY-gained ,drug patent expiry ,HCV ,hepatitis C treatment ,Medicine (General) ,R5-920 ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Katherine Heath1,2 1Mathematical Ecology Research Group, Department of Zoology, University of Oxford, Oxford OX1 3PS, UK; 2New College, Oxford OX1 3BN, UK Background: Cost-benefit analyses are crucial to inform treatment policies, particularly when the cost of patented drugs is very high. The cost of patented drugs is the limiting factor in hepatitis C treatment. However, hepatitis C drug costs are expected to fall following patent expiration, due to generic drug introduction. Methods: An existing mathematical model by Shih et al was extended to consider lower-cost future generics in health economic models of hepatitis C. The model compared the cost-effectiveness of treating patients now with patented drugs vs postponing treatment until after patent expiration. Results: For ledipasvir-sofosbuvir, this study finds that it is almost always more cost effective to treat hepatitis C with high-cost patented drugs immediately rather than waiting for patent expiry. For ledipasvir-sofosbuvir, a generic would need to enter the market at
- Published
- 2018
6. Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations
- Author
-
Karapetyan, Lilit, primary, Iheagwara, Uzoma K, additional, Olson, Adam C, additional, Chmura, Steven J, additional, Skinner, Heath K, additional, and Luke, Jason J, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Keeping kids in school: modelling school-based testing and quarantine strategies during the COVID-19 pandemic in Australia.
- Author
-
Abeysuriya, RG, Sacks-Davis, R, Heath, K, Delport, D, Russell, FM, Danchin, M, Hellard, M, McVernon, J, Scott, N, Abeysuriya, RG, Sacks-Davis, R, Heath, K, Delport, D, Russell, FM, Danchin, M, Hellard, M, McVernon, J, and Scott, N
- Abstract
BACKGROUND: In 2021, the Australian Government Department of Health commissioned a consortium of modelling groups to generate evidence assisting the transition from a goal of no community COVID-19 transmission to 'living with COVID-19', with adverse health and social consequences limited by vaccination and other measures. Due to the extended school closures over 2020-21, maximizing face-to-face teaching was a major objective during this transition. The consortium was tasked with informing school surveillance and contact management strategies to minimize infections and support this goal. METHODS: Outcomes considered were infections and days of face-to-face teaching lost in the 45 days following an outbreak within an otherwise COVID-naïve school setting. A stochastic agent-based model of COVID-19 transmission was used to evaluate a 'test-to-stay' strategy using daily rapid antigen tests (RATs) for close contacts of a case for 7 days compared with home quarantine; and an asymptomatic surveillance strategy involving twice-weekly screening of all students and/or teachers using RATs. FINDINGS: Test-to-stay had similar effectiveness for reducing school infections as extended home quarantine, without the associated days of face-to-face teaching lost. Asymptomatic screening was beneficial in reducing both infections and days of face-to-face teaching lost and was most beneficial when community prevalence was high. INTERPRETATION: Use of RATs in school settings for surveillance and contact management can help to maximize face-to-face teaching and minimize outbreaks. This evidence supported the implementation of surveillance testing in schools in several Australian jurisdictions from January 2022.
- Published
- 2023
8. Can we identify individuals with an ALPL variant in adults with persistent hypophosphatasaemia?
- Author
-
Tornero, C., Navarro-Compán, V., Tenorio, J. A., García-Carazo, S., Buño, A., Monjo, I., Plasencia-Rodriguez, C., Iturzaeta, J. M., Lapunzina, P., Heath, K. E., Balsa, A., and Aguado, P.
- Published
- 2020
- Full Text
- View/download PDF
9. Quantification and specification of agricultural by-products as local resources for mycelium-bound composites.
- Author
-
Yoo, J G, Heath, K, Wisniewska, M H, and Heisel, F
- Published
- 2023
- Full Text
- View/download PDF
10. Novel FLNB Variants in Seven Argentinian Cases with Spondylocarpotarsal Synostosis Syndrome
- Author
-
Ramos-Mejía, R, additional, del Pino, M, additional, Aza-Carmona, M, additional, Abbate, S, additional, Obregon, M G., additional, Heath, K E., additional, and Fano, V, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Real-time ultrasound angiography using superharmonic dual-frequency (2.25 MHz/30 MHz) cylindrical array: In vitro study
- Author
-
Wang, Zhuochen, Martin, Heath K., Dayton, Paul A., and Jiang, Xiaoning
- Published
- 2018
- Full Text
- View/download PDF
12. EHR Query Language (EQL) - A Query Language for Archetype-Based Health Records.
- Author
-
Chunlan Ma, Heath K. Frankel, Thomas Beale 0001, and Sam Heard
- Published
- 2007
- Full Text
- View/download PDF
13. Intent to Be Vaccinated against COVID-19 in Victoria, Australia
- Author
-
Heath, K, Altermatt, A, Saich, F, Pedrana, A, Fletcher-Lartey, S, Bowring, AL, Stoove, M, Danchin, M, Kaufman, J, Gibney, KB, Hellard, M, Heath, K, Altermatt, A, Saich, F, Pedrana, A, Fletcher-Lartey, S, Bowring, AL, Stoove, M, Danchin, M, Kaufman, J, Gibney, KB, and Hellard, M
- Abstract
BACKGROUND: High vaccine uptake requires strong public support, acceptance, and willingness. METHODS: A longitudinal cohort study gathered survey data every four weeks between 1 October 2020 and 9 November 2021 in Victoria, Australia. Data were analysed for 686 participants aged 18 years and older. RESULTS: Vaccine intention in our cohort increased from 60% in October 2020 to 99% in November 2021. Vaccine intention increased in all demographics, but longitudinal trends in vaccine intention differed by age, employment as a healthcare worker, presence of children in the household, and highest qualification attained. Acceptance of vaccine mandates increased from 50% in October 2020 to 71% in November 2021. Acceptance of vaccine mandates increased in all age groups except 18-25 years; acceptance also varied by gender and highest qualification attained. The main reasons for not intending to be vaccinated included safety concerns, including blood clots, and vaccine efficacy. CONCLUSION: COVID-19 vaccination campaigns should be informed by understanding of the sociodemographic drivers of vaccine acceptance to enable socially and culturally relevant guidance and ensure equitable vaccine coverage. Vaccination policies should be applied judiciously to avoid polarisation.
- Published
- 2022
14. Thermodynamic and Dynamic Properties of Polymers in Liquid and Supercritical Solvents
- Author
-
Melnichenko, Yuri B., Wignall, G. D., Brown, W., Kiran, E., Cochran, H. D., Salaniwal, S., Heath, K., VanHook, W. A., Stamm, M., Dadmun, M. D., editor, Van Hook, W. Alexander, editor, Noid, Donald W., editor, Melnichenko, Yuri B., editor, and Sumpter, Bobby G., editor
- Published
- 2002
- Full Text
- View/download PDF
15. Additional file 1 of Biochemical algorithm to identify individuals with ALPL variants among subjects with persistent hypophosphatasaemia
- Author
-
Tornero, C., Navarro-Comp��n, V., Bu��o, A., Heath, K. E., D��az-Almir��n, M., Balsa, A., Tenorio, J. A., Quer, J., and Aguado, P.
- Abstract
Additional file 1. Table S1: Probability of binary responses for ALP and substrates' threshold levels vis-��-vis the interaction of time and genetic status.
- Published
- 2022
- Full Text
- View/download PDF
16. Additional file 2 of Biochemical algorithm to identify individuals with ALPL variants among subjects with persistent hypophosphatasaemia
- Author
-
Tornero, C., Navarro-Comp��n, V., Bu��o, A., Heath, K. E., D��az-Almir��n, M., Balsa, A., Tenorio, J. A., Quer, J., and Aguado, P.
- Abstract
Additional file 2. Table S2: List of subjects included in +GT group with heterozygous pathogenic or likely pathogenic ALPL variants.
- Published
- 2022
- Full Text
- View/download PDF
17. Calidad de vida en pacientes con fosfatasa alcalina persistentemente baja portadores o no de mutaciones del gen ALPL
- Author
-
Santurtun Zarrabeitia, Maite, Mediavilla Martínez, E., Vega, A. I., Gallego, N., Heath, K., Tenorio, J., Lapunzina, P., Riancho Moral, José Antonio, Riancho Zarrabeitia, Leyre, and Universidad de Cantabria
- Abstract
Introducción: Los niveles bajos de fosfatasa alcalina (FAlc) en suero son el sello distintivo de la hipofosfatasia, un trastorno debido a variantes patogénicas del gen ALPL. Nuestro objetivo fue determinar la calidad de vida relacionada con la salud en adultos con fosfatasa alcalina baja y explorar las diferencias entre pacientes con y sin mutaciones en ALPL. Material y métodos: Estudiamos 35 pacientes adultos con FAlc persistentemente baja en los que se excluyeron causas adquiridas y se secuenció ALPL. Se compararon con 35 controles de igual edad. Se completaron tres cuestionarios sobre dolor (Brief Pain Inventory, BPI), discapacidad física (Health Assessment Questionnaire Disability Index, HAQ-DI) y calidad de vida relacionada con la salud (36-item Short-Form Health Survey, SF-36). Resultados: Las puntuaciones medias de intensidad e interferencia del dolor en el BPI fueron mayores en el grupo de pacientes (p=0,04 y 0,004, respectivamente). Todos los dominios del instrumento HAQ tendieron a puntuar peor en los pacientes, con diferencias significativas en la puntuación de "alcance" (p=0,037) y la puntuación media general (0,23 frente a 0,09; p=0,029). Los pacientes puntuaron peor que los controles en varias dimensiones del SF-36 (rol físico, p=0,039; dolor corporal p=0,046; rol emocional, p=0,025). Sin embargo, los pacientes con y sin variantes patogénicas puntuaron de manera similar en todas las pruebas, sin diferencias significativas entre los grupos. Conclusiones: Los pacientes con niveles persistentemente bajos de FAlc tienen puntuaciones significativamente peores en dolor corporal y otras dimensiones de calidad de vida relacionadas con la salud, sin diferencias entre pacientes con y sin variantes patogénicas en el gen ALPL. Esto es consistente con la hipótesis de que estos últimos presenten mutaciones en regiones reguladoras, habitualmente no secuenciadas, del gen ALPL.
- Published
- 2022
18. Copy number variants of Ras/MAPK pathway genes in patients with isolated cryptorchidism
- Author
-
Rodríguez, F., Vallejos, C., Giraudo, F., Unanue, N., Hernández, M. I., Godoy, P., Célis, S., Martín‐Arenas, R., Palomares‐Bralo, M., Heath, K. E., López, M. T., and Cassorla, F.
- Published
- 2017
- Full Text
- View/download PDF
19. Supporting Special-Purpose Health Care Models via Web Interfaces.
- Author
-
James R. Warren, Heath K. Frankel, Joseph T. Noone, and Berend-Jan van der Zwaag
- Published
- 2000
- Full Text
- View/download PDF
20. Optimal Sensing Vector Orientation For Maximal R-Wave Amplitude, Implications for Insertable Cardiac Monitor (ICM) Implantation
- Author
-
Pitman, B., primary, Zanker, A., additional, Lim, M., additional, McLoughney, J., additional, Tarone, R., additional, McInnes, K., additional, Heath, K., additional, Gieve, M., additional, Evans, S., additional, Wong, C., additional, Sanders, P., additional, and Lau, D., additional
- Published
- 2022
- Full Text
- View/download PDF
21. List of contributors
- Author
-
Aïtcin, P.-C., primary, Alexander, M.G., additional, Allen, S.N., additional, Andrade, C., additional, Baz, M., additional, Braestrup, M.W., additional, Fan, Z., additional, Gjørv, O.E., additional, Gulikers, J., additional, Heath, K., additional, Langley, W.S., additional, Li, K., additional, Li, Q., additional, Mackie, K.P., additional, Mindess, S., additional, Moore, G.A.C., additional, Nganga, G., additional, Otieno, M., additional, Pérez, R., additional, Rebolledo, N., additional, Santhanam, M., additional, Smith, P.E., additional, Tavares, F., additional, and Thomas, M., additional
- Published
- 2016
- Full Text
- View/download PDF
22. Marinas in the Arabian Gulf region
- Author
-
Heath, K., primary
- Published
- 2016
- Full Text
- View/download PDF
23. Biochemical algorithm to identify individuals with ALPL variants among subjects with persistent hypophosphatasaemia
- Author
-
Tornero, C., Navarro-Compán, V., Buño, A., Heath, K. E., Díaz-Almirón, M., Balsa Criado, Alejandro, Tenorio, J. A., Quer, J., and Aguado, P.
- Subjects
ALPL ,Adult ,hypophosphatasaemia ,Medicina ,Hypophosphatasia ,General Medicine ,Alkaline Phosphatase ,Bone and Bones ,Machine Learning ,metabolic bone diseases ,Pyridoxal Phosphate ,Humans ,Pharmacology (medical) ,Genetics (clinical) - Abstract
Background Hypophosphatasia (HPP) is a rare and underdiagnosed condition characterized by deficient bone and teeth mineralization. The aim of this study was first, to evaluate the diagnostic utility of employing alkaline phosphatase (ALP) threshold levels to identify adults with variants in ALPL among individuals with persistently low ALP levels and second, to determine the value of also including its substrates (serum pyridoxal-5′-phosphate—PLP—and urinary phosphoetanolamine-PEA) for this purpose in order to create a biochemical algorithm that could facilitate the diagnostic work-up of HPP. Results The study population comprised 77 subjects with persistent hypophosphatasaemia. They were divided into two groups according to the presence (+GT) or absence (−GT) of pathogenic ALPL variants: 40 +GT and 37 −GT. Diagnostic utility measures were calculated for different ALP thresholds and Receiver Operating Characteristic (ROC) curves were employed to determine PLP and PEA optimal cut-off levels to predict the presence of variants. The optimal threshold for ALP was 25 IU/L; for PLP, 180 nmol/L and for PEA, 30 µmol/g creatinine. Biochemical predictive models were assessed using binary logistic regression analysis and bootstrapping machine learning technique and results were then validated. For ALP Conclusions In this study, we propose a biochemical predictive model based on the threshold levels of the main biochemical markers of HPP (ALP 180 nmol/L) that when combined, seem to be very useful to identify individuals with ALPL variants.
- Published
- 2021
24. Adaptive windowing in contrast-enhanced intravascular ultrasound imaging
- Author
-
Lindsey, Brooks D., Martin, Heath K., Jiang, Xiaoning, and Dayton, Paul A.
- Published
- 2016
- Full Text
- View/download PDF
25. A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies
- Author
-
Tenorio, J., Navas, P., Barrios, E., Fernández, L., Nevado, J., Quezada, C. A., López-Meseguer, M., Arias, P., Mena, R., Lobo, J. L., Alvarez, C., Heath, K., Escribano-Subías, P., and Lapunzina, P.
- Published
- 2015
- Full Text
- View/download PDF
26. The Localization of the Products of the c-cbl and v-cbl Oncogenes During Mitosis and Transformation
- Author
-
Langdon, W. Y., Heath, K. G., Blake, T. J., Capron, A., editor, Compans, R. W., editor, Cooper, M., editor, Koprowski, H., editor, McConnell, I., editor, Melchers, F., editor, Oldstone, M., editor, Olsnes, S., editor, Potter, M., editor, Saedler, H., editor, Vogt, P. K., editor, Wagner, H., editor, Wilson, I., editor, Potter, Michael, editor, and Melchers, Fritz, editor
- Published
- 1992
- Full Text
- View/download PDF
27. Supporting special-purpose health care models via adaptive interfaces to the web.
- Author
-
James R. Warren, Heath K. Frankel, and Joseph T. Noone
- Published
- 2002
- Full Text
- View/download PDF
28. Dichaete, a Sox2 homologue, prevents activation of cell death in multiple developmental contexts
- Author
-
Katherine Harding, Kristin White, and Heath K
- Subjects
Programmed cell death ,SOX2 ,Reaper ,Transcription (biology) ,Biology ,Hox gene ,Enhancer ,Transcription factor ,Neural stem cell ,Cell biology - Abstract
Precisely regulated cell death plays a critical role in normal development and is controlled by the balance of pro-apoptotic and anti-apoptotic signals. In Drosophila, transcription of the clustered cell death activators grim and reaper is turned on in the developing nervous system to eliminate neural stem cells at the end of embryonic development. This transcription is activated by a pulse of the Hox gene abdominal-A. We show here that the Sox2 homologue Dichaete inhibits neural stem cell death when overexpressed, and loss of Dichaete promotes premature neural stem cell death. The anti-apoptotic activity of Dichaete opposes the pro-apoptotic factors abdominal-A, as well as the transcription factor grainyhead. The function of all three genes impinge on an enhancer that regulates the transcription of grim and reaper. Furthermore, we find that the balance between abdominal-A and Dichaete is likely to regulate the death of other cells during development, including cells in the developing midline, the developing hindgut, and in the early abdominal epidermis. Loss of Dichaete results in premature death in these tissues. This death can be rescued by the deletion of the enhancer region between grim and reaper. These data suggest that Dichaete functions to inhibit cell death activated by abdominal-A in multiple developmental contexts.
- Published
- 2021
29. SARS-CoV-2 infection and risk of clinical sequelae during the post-acute phase: a retrospective cohort study
- Author
-
Dasmariñas Mc, Ken Cohen, Heath K, Jubilo Kg, Marc Lipsitch, Samranvedhya J, Daugherty Se, and Yinglong Guo
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,Hazard ratio ,Absolute risk reduction ,Amnesia ,Retrospective cohort study ,medicine.disease ,Confidence interval ,Diabetes mellitus ,medicine ,Observational study ,medicine.symptom ,business ,Cohort study - Abstract
ObjectiveClinical sequelae have not been well characterized during the post-acute phase of SARS-CoV-2 among adults 18 to 65 years old, and this study sought to fill that gap by evaluating excess risk and relative hazards for developing incident clinical sequelae during the post-acute phase.DesignRetrospective cohort study including three propensity-matched groups.SettingThis study merged three data sources from a large United States health plan: a large national administrative claims database, an outpatient lab testing database, and an inpatient hospital admissions database.ParticipantsIndividuals 18 to 65 years old with continuous health plan enrollment from January 2019 to date of SARS-CoV-2 diagnosis. Three comparator groups were identified and propensity-score matched to individuals infected with SARS-CoV-2: a 2020 comparator group, a historical 2019 comparator group and a historical comparator group with viral lower respiratory tract illness (vLRTI).Main outcome measuresOver 50 clinical sequelae during the post-acute phase (index date + 21 days) were ascertained using ICD-10 codes. Excess risk due to SARS-CoV-2 during the 4 months following the acute phase of illness and hazard ratios with 95% Bonferroni-corrected confidence intervals were calculated.ResultsThis study found 14% of adults ≤65 years of age who were infected with SARS-CoV-2 (n=193113) had at least one new clinical sequelae that required medical attention during the post-acute phase of illness. When considering risk for specific sequelae attributable to SARS-Cov-2 infection during the post-acute phase, clinical outcomes including chronic respiratory failure, cardiac arrythmia, hypercoagulability, encephalopathy, peripheral neuropathy, amnesia (memory difficulty), diabetes, liver test abnormalities, myocarditis, anxiety and fatigue were significantly elevated compared to the three propensity-matched comparator groups (2020, 2019, vLRTI). Significant risk differences due to SARS-CoV-2 infection ranged from 0.02 to 2.26 per 100 people and hazard ratios ranged from 1.24 to 25.65 when compared to the 2020 comparator group.ConclusionsOur results confirm excess risk for developing clinical sequelae due to SARS-CoV-2 during the post-acute phase, including specific types of sequelae less commonly seen among other viral illnesses. Although individuals who were older, had pre-existing conditions, and were hospitalized due to COVID-19 were at greatest excess risk, younger adults (≤50 years), adults who did not have pre-existing conditions or adults who were not hospitalized due to COVID-19 were still at elevated risk for developing new clinical sequelae. The elevated risk for incident sequelae during the post-acute phase is relevant for healthcare planning.Summary BoxWhat is already known on this topicSmall observational studies and case reports of hospitalized patients have shown some COVID-19 survivors suffer from short- and long-term sequelae. Few studies have characterized the excess risk of clinical sequelae attributable to SARS-CoV-2 during the post-acute phase among adults ≤65 years of age in a large generalizable sample.What this study addsThis study found 14% of individuals ≤65 years of age who were infected with SARS-CoV-2 (n=193113) had a diagnosis of at least one new sequelae that required medical attention during the post-acute phase of illness. Elevated risk for specific clinical sequelae during the post-acute phase of illness was noted across a range of organ systems including cardiovascular, neurologic, kidney, respiratory, and mental health complications. The risk for incident sequelae increases with age, pre-existing conditions, and hospitalization for COVID-19; however, even among adults ≤ 50 years of age and individuals without pre-existing conditions or hospitalization due to COVID-19, risk for some clinical sequelae is still elevated. These results indicate where additional diagnostic follow-up, rehabilitation, and symptom management may be warranted among younger adults with milder infection.
- Published
- 2021
30. Southern College and University Faculty Research Resources in Physical Science and Engineering Fields
- Author
-
Riggs, Heath K.
- Published
- 1953
31. Inter-State Cooperation in Education
- Author
-
Riggs, Heath K.
- Published
- 1953
32. READER'S OUTLOOK.
- Author
-
Slayter, Michael and Rada, Heath K.
- Subjects
CONGREGATIONALISM ,CHRISTIAN leadership - Published
- 2024
33. The phenotypic spectrum of Chitayat syndrome: Six additional affected individuals
- Author
-
Suter, A., Perez, A. Abad, Santos-Simarro, F., Toerring, P., Ramos-Mejia, R., Heath, K., Huckstadt, V., Parron-Pajares, M., Mensah, M., Huelsemann, W., Holtgrewe, M., Mundlos, S., Kornak, U., Bartsch, O., and Ehmke, N.
- Published
- 2020
34. Chronic Disease Coordinated Care Planning: Flexible, Task-Centered Decision Support.
- Author
-
James R. Warren, Gleb Beliakov, Joseph T. Noone, and Heath K. Frankel
- Published
- 1999
- Full Text
- View/download PDF
35. Rates of new infections in British Columbia continue to decline at a faster rate than in other Canadian regions
- Author
-
Hogg, R S, Nosyk, B, Harrigan, P R, Lima, V D, Chan, K, Heath, K, Wood, E, Kerr, T, and Montaner, J SG
- Published
- 2013
- Full Text
- View/download PDF
36. Mathematical and behavioural ecology of mosquitoes in response to environmental change
- Author
-
Heath, K, Bonsall, M, and Wilson, A
- Abstract
Mosquito-borne disease presents an enormous global health challenge. Malaria remains the leading cause of stillbirth, dengue fever affects over 300 million people each year and chikungunya has caused numerous large outbreaks over the last two decades. Mosquito-borne diseases continue to affect some of the most socioeconomically disadvantaged and vulnerable sectors of society; higher levels of mosquito-borne disease occur in developing regions and disproportionately affect children. Rapid changes in climate, land use and human movement all have consequences for the ecology of mosquitoes and, consequently, the diseases they spread. Incidentally, it is thought that rapid global environmental and climate change are likely to most severely affect developing nations. Therefore, it is imperative that mosquito control initiatives acknowledge the effects of environmental change upon mosquito life history to have maximum impact. In this thesis I endeavour to understand some of the mechanisms by which environmental heterogeneity and environmental change affect mosquito populations. In Chapter 1, I introduce important aspects of mosquito ecology and suggest primary mechanisms by which environmental change affects mosquito ecology. Chapter 2 presents a model of Aedes aegypti population dynamics in response to climate change in Brazil. The model estimated mosquito populations to increase across most of Brazil as a consequence of changes in temperature and precipitation. Seasonal patterns in mosquito populations were also predicted to be disrupted. Understanding the finer details of the effects of environmental change on specific mosquito life-history traits is also imperative. This is because (a) environmental perturbation has unimodal effects at multiple life-cycle stages and (b) mathematical population models must be accurately parameterised to reflect biological traits. Chapter 3 considers one such trait – larval density dependence – and demonstrates that nutritional availability modifies density dependence in Aedes aegypti. Therefore, density dependence in Aedes aegypti larvae is a multi-dimensional process that requires mechanistic empirical study designs. In Chapter 4 I present a methodological approach by which environmental heterogeneity can be accounted for in models of mosquito population dynamics, using Aedes polynesiensis in French Polynesia as a study system. I demonstrate that different patterns of environmental change can have spatially non-linear effects upon mosquito populations. In Chapter 5, I synthesise the preceding findings and place them in a broader ecological context. For successful mosquito control, there must be extensive empirical research and theoretical modelling undertaken to catalogue the ways in which environmental change affects mosquito ecology. This thesis endeavours to provide some movement towards this. However, the extent to which future mosquito-borne disease outbreaks is mitigated depends more than ever upon what we do now to mitigate damaging changes in land use and climate.
- Published
- 2020
37. Modelling the impact of relaxing COVID-19 control measures during a period of low viral transmission
- Author
-
Scott, N, Palmer, A, Delport, D, Abeysuriya, R, Stuart, RM, Kerr, CC, Mistry, D, Klein, DJ, Sacks-Davis, R, Heath, K, Hainsworth, SW, Pedrana, A, Stoove, M, Wilson, D, Hellard, ME, Scott, N, Palmer, A, Delport, D, Abeysuriya, R, Stuart, RM, Kerr, CC, Mistry, D, Klein, DJ, Sacks-Davis, R, Heath, K, Hainsworth, SW, Pedrana, A, Stoove, M, Wilson, D, and Hellard, ME
- Abstract
OBJECTIVES: To assess the risks associated with relaxing coronavirus disease 2019 (COVID-19)-related physical distancing restrictions and lockdown policies during a period of low viral transmission. DESIGN: Network-based viral transmission risks in households, schools, workplaces, and a variety of community spaces and activities were simulated in an agent-based model, Covasim. SETTING: The model was calibrated for a baseline scenario reflecting the epidemiological and policy environment in Victoria during March-May 2020, a period of low community viral transmission. INTERVENTION: Policy changes for easing COVID-19-related restrictions from May 2020 were simulated in the context of interventions that included testing, contact tracing (including with a smartphone app), and quarantine. MAIN OUTCOME MEASURE: Increase in detected COVID-19 cases following relaxation of restrictions. RESULTS: Policy changes that facilitate contact of individuals with large numbers of unknown people (eg, opening bars, increased public transport use) were associated with the greatest risk of COVID-19 case numbers increasing; changes leading to smaller, structured gatherings with known contacts (eg, small social gatherings, opening schools) were associated with lower risks. In our model, the rise in case numbers following some policy changes was notable only two months after their implementation. CONCLUSIONS: Removing several COVID-19-related restrictions within a short period of time should be undertaken with care, as the consequences may not be apparent for more than two months. Our findings support continuation of work from home policies (to reduce public transport use) and strategies that mitigate the risk associated with re-opening of social venues.
- Published
- 2020
38. A non-pathogenic pseudoautosomal region 1 copy number variant downstream of SHOX
- Author
-
Benito-Sanz, S., Aragones, A., Gracia, R., Campos-Barros, A., and Heath, K. E.
- Published
- 2011
- Full Text
- View/download PDF
39. Clinical and Molecular Evaluation of SHOX/PAR1 Duplications in Léri-Weill Dyschondrosteosis (LWD) and Idiopathic Short Stature (ISS)
- Author
-
Benito-Sanz, S., Barroso, E., Heine-Suñer, D., Hisado-Oliva, A., Romanelli, V., Rosell, J., Aragones, A., Caimari, M., Argente, J., Ross, J. L., Zinn, A. R., Gracia, R., Lapunzina, P., Campos-Barros, A., and Heath, K. E.
- Published
- 2011
40. Mutualism variation in the nodulation response to nitrate
- Author
-
HEATH, K. D., STOCK, A. J., and STINCHCOMBE, J. R.
- Published
- 2010
- Full Text
- View/download PDF
41. Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes the TRIGR randomized clinical trial
- Author
-
Knip M., Akerblom H. K., Altaji E., Becker D., Bruining J., Castano L., Danne T., De Beaufort C., Dosch H. -M., Dupre J., Fraser W. D., Howard N., Ilonen J., Konrad D., Kordonouri O., Krischer J. P., Lawson M. L., Ludvigsson J., Madacsy L., Mahon J. L., Ormisson A., Palmer J. P., Pozzilli P., Savilahti E., Serrano-Rios M., Songini M., Taback S., Vaarala O., White N. H., Virtanen S. M., Wasikowa R., Mandrup-Poulsen T., Arjas E., Lernmark A., Laara E., Schmidt B., Hyytinen M., Koski K., Koski M., Merentie K., Pajakkala E., Reunanen A., Salonen M., Terhonen T., Virkkunen S., Cuthbertson D., Gainer B., Hadley D., Malloy J., Nallamshetty L., Shanker L., Bradley B., Lough G., Fraser W., Sermer M., Taback S. P., Franciscus M., Nucci A., Palmer J., Alahuhta K., Barlund S., Korhonen T., Kovanen L., Lehtonen E., Niinisto S., Pekkala M., Sorkio S., Toivanen L., Vahatalo L., Uusitalo U., Ohman T., Bongiorno R., Catteau J., Fraser G., Lloyd M., Crock P., Giles M., Siech K., See D. W., Brown C., Craig M., Johnston A., Bere L. J., Clarson C. L., Jenner M., McManus R., Renato N., Lovell M., Higo D., Kent N., Kwan J., Marshall C., Metzger D., Chanoine J. -P., Stewart L., Thompson D., Edwards A., Lange I., Mercer J., Pacaud D., Josephine H., Schwarz W., Stephure D. K., Boer J., Chatur T., Chick C., Couch B., Demianczuk N., Girgis R., Marks S., Ryan E., Thompson M., Dean H. J., Grant L., Hamelin K., LaForte J., Murphy L., Catte D., Schneider C., Sellers E. A. C., Woo V., Boland A., Clark H. D., Cooper T., Gruslin A., Karovitch A., Keely E., Malcolm J. C., Sauro V., Tawagi G. F., Andrighetti S., Arnold G., Barrett J., Blumer I., Daneman D., Donat D., Ehrlich R., Feig D., Gottesman I., Gysler M., Karkanis S., Kenshole A., Knight B., Lackie E., Lewis V., Martin M. J., Maxwell C., Oliver G., Panchum P., Shilletto N., Simone A., Skidmore M., Turrini T., Wong S., Allen C., Belanger L., Bouchard I., Ferland S., Frenette L., Garrido-Russo M., Leblanc M., Imbeault J., Morin V., Olivier G., Weisnagell J., Costain G., Dornan J., Heath K., MacSween M. -C., McGibbon A., Ramsay C., Sanderson F., Sanderson S., Benabdesselam L., Gonthier M., Huot C., Thibeault M., Laforte D., Legault L., Perron P., Armson A., Canning P., Cummings E. A., Ivanko V., McLeod L., Mokashi A., Scott K., Bridger T., Crane J., Crummell C., Curtis J. C., Dawson C., Joyce C., Newhook L. A., Newman S., Druken E., Begum-Hasan J., Breen A., Houlden R., Woods M., Carrson G., Kelly S., Martel M. J., Penner M., Sankaran K., Hardy-Brown K., King N., White R. A., Park M., Popkin J., Robson L., Coles K., Al Taji E., Cerna M., Cerny M., Francova H., Hainerova I., Kothankova H., Koukalova R., Krakorova V., Mendlova P., Sitova R., Stechova K., Vavrinec J., Vosahlo J., Zlatohlavkova B., Brazdova L., Faksova P., Gregorova D., Kantor L., Malkova K., Venhacova J., Venhacova P., Cipra A., Skvor J., Budejovice C., Tomsikova Z., Botkova-Krauseova H., Mockova A., Paterova P., Gogelova P., Kandrnalova J., Einberg U., Jakovlev U., Posiadlo S., Rannaste E., Raukas R., Riikjarv M. -A., Valla K., Astover V., Kirss A., Retpap J., Taht E., Tillmann V., Vahtra S., Heikkila M., Hirvasniemi M., Luopajarvi K., Johansson S., Kleemola P., Laukkanen E., Parkkola A., Pigg H. -M., Puttonen H., Renlund M., Salonen K., Suomalainen H., Tenkula T., Teramo K., Jarvenpaa A. -L., Hamalainen A. -M., Jussila R., Kiiveri S., Haavisto H., Holopainen S., Kupiainen H., Leeve T., Lumme K., Nironen T., Tenhola S., Tiilikainen T., Keinonen H., Lautala P., Salonen P., Vesanto M., Aspholm A. S., Asunta P., Ikavalko H., Jason E., Jaminki S., Kekki P., Koskinen M., Lehtimaki S., Lahde J., Makela M., Peltoniemi S., Poutiainen L., Ranta K., Salonsaari T., Sarviharju-Tujula S. -L., Selvenius J., Siljander H., Haanpaa P. -L., Holm C., Juutilainen A., Jarvelainen V., Kangaskolkka-Keskilohko A. -M., Laino E., Marjamaki L., Suominen E., Ylitalo S., Hokkanen M., Lounamaa R., Matikainen M., Nuuja A., Paalanen I., Puupponen A. R., Salo-Edwards H., Alanne S., Kultti T., Linjama H., Muhonen K., Vaaraniemi M., Talvitie T., Backman M., Hanhijarvi R., Koivula P., Lindstrom K., Martikainen A., Nurmi P., Bjork A., Huopio H., Komulainen J., Lehtomaki S., Muikku E., Pesola J., Sankilampi U., Arkkola T., Hekkala A., Jurvakainen S., Koivikko M. -L., Kahonen M., Leinonen E., Mykkanen T., Pohjola H., Riikonen K., Niittyvuopio A., Stenius A., Tapanainen P., Veijola R., Alar A., Jovio S., Korpela P., Makinen E., Hietanen L., Kivisto J., Kaar M. -L., Lehtimaki P., Mustila T., Popov E., Saatela S., Taittonen L., Ahtiainen K., Laaksonen N., Luoto M., Viitala J., Virransalo R., Nykanen P., Paajanen S., Parkkinen S., Pyrhonen H., Sarkka T., Aschemeier B., Bektas S., Biester T., Datz N., Deiss D., Fath M., Lupke K., Muller B., Nestoris C., Rothes S., Sadeghian E., Semler K., Arato A., Krikovszky D., Nobilis A., Szenasi J., Benevento D., Anguissola G. B., Biagioni M., Bizzarri C., Cherubini V., Ferrito L., Giordano C., Giorgetti C., Khazrai Y. M., Kyanvash S., Maddaloni E., Napoli A., Piergiovanni F., Pitocco D., Suraci T., Tabacco G., Valente L., Visalli N., Carboni M. B., Cavallo R., Cau V., Isola C., Ledda A., Loddo M., Mannu C., Pettinau M., Pisano S., Porceddu M., Putzu C., Rita A., Peters D., Schierloh U., Bisschoff M., Blonk L., Lappenschaar T., Manai B., Seesink M., Sperling-Conrad M., Verhagen M., Zoethout J. A., Basiak A., Chalas M., Chesiak M., Gramza A., Iwankiewicz J., Sieradzan E., Wikiera B., Ciechanowska M., Dziatkowiak H., Futona B., Gorska A., Glowacka-Wony M., Kaim I., Klich B., Starzyk J., Wolanin M., Tokarska L., Chucherco D., Deja G., Firek-Pedras M., Jarosz-Chobot P., Kalina M., Kutrowska-Adamusiak K., Minkina-Pedras M., Muchaka-Bianga M., Bodalski J., Mlynarski W., Szadkowska A., Cieslak A., Cypryk K., Dziatosz K., Jastzebowska J., Krysiak A., Szymanska U., Wilcznski J., Zawodniak-Szalapska M., Aguay A., Bilbao J. R., Chueca M., Cortazar A., Echarte G., Frutos T. G., Jimenez P., Martul P., Moreno A., Oyarzabal M., Rica I., Salgado Y., Martinez-Larrad M. T., Hawkins F. G., Hernandez R., Herranz L., Pallardo L. F., Deibarra L. S., Fernandez B. H., Luis J. L., Ortiz-Quintana L., Recarte P. P., Arnau D. R., Aronsson L., Boden S., Fredriksson J., Isacsson E., Johansson I., Karlsson E., Lock C., Sandstrom A. -M., Konefal M. S., Andreasson C., Dahlstrom U., Hanas R., Lundqvist K., Windell L., Jansson I., Karlsson A. -K., Lindbladh B., Odenman I., Pettersson C., Sundberg F., Sundqvist M., Aronsson S., Bellman I., Bengtsson A. -B., Lyden G. -B., Nilsson N. -O., Soderblom M., Unt C., Augustsson M., Bengtsson M., Fors H., Helmrich A., Johansson T. O., Andersson A. -C., Boiard-Stomlid A., Hellgren G., Kallsholm H., Lindqvist J., Nilsson M., Nordwall M., Stromstedt C., Ahsberg C., Lindh A., Lindhe C., Samuelsson C., Wiik A., Edenwall H., Ljumgcrantz M., Persson I. -B., Strigard E., Svensson B. -L., Aman J., Breivik G. -E., Detlofsson I. -L., Kroon M., Sarnblad S., Johansson C., Ilvered R., Lundberg A., Akesson K., Beccarelli A., Gadient M., Rappold-Amrein C., Schoenle E., Daftary A., Damagro-Elias M. E., Gilmour C., Klein M. B., Lain C., Salerno D., Smith M. E., Vats K., Pfaff D. J., Malone P., Mansfield P., Munns M., Nickel K., Pompilio K., Siemion W., Taculad R., Van Horn K., Zdanadewic M., Chambliss C., Jones J., Sadler M., Tanner-Blasiar M., Bell C., Camper N., Devaskar S., Devaskar U., Horowitz H., Rogers L., Shannahan R., Silk K., Bermudez Z., Colon R., Frazer T., Martinez-Nieves B., Torres J., Vega J., Chan M., Cook S., Goland R., Greenberg E., Jules N., Montes J., Nelson M., Parra-Valencia Z., Schachner H., Softness B., Kiviniemi M., Suomenin R., Alexander A., Hyrckowian E., Nichol L., Trucco M., Karjalainen E., Louhio T., Sarnesto A., Valtonen E., Davydova B., Helander S., Hamalainen J., Harkonen T., Joutsjoki L., Kararic M., Latva-Koivisto M., Lonn E., Nurmi T., Ollila I., Rinkinen J., Ronkainen M., Tukiainen H., Cederlof A., Kiikeri M., Tsupari S., Cheng R., Bryant K., Chan Y., Maezawa Y., Paltser G., Rasavi R., Tsui H., Winer S., Wu P., Yantha J., Pediatrics, Knip M., Akerblom H.K., Altaji E., Becker D., Bruining J., Castano L., Danne T., De Beaufort C., Dosch H.-M., Dupre J., Fraser W.D., Howard N., Ilonen J., Konrad D., Kordonouri O., Krischer J.P., Lawson M.L., Ludvigsson J., Madacsy L., Mahon J.L., Ormisson A., Palmer J.P., Pozzilli P., Savilahti E., Serrano-Rios M., Songini M., Taback S., Vaarala O., White N.H., Virtanen S.M., Wasikowa R., Mandrup-Poulsen T., Arjas E., Lernmark A., Laara E., Schmidt B., Hyytinen M., Koski K., Koski M., Merentie K., Pajakkala E., Reunanen A., Salonen M., Terhonen T., Virkkunen S., Cuthbertson D., Gainer B., Hadley D., Malloy J., Nallamshetty L., Shanker L., Bradley B., Lough G., Fraser W., Sermer M., Taback S.P., Franciscus M., Nucci A., Palmer J., Alahuhta K., Barlund S., Korhonen T., Kovanen L., Lehtonen E., Niinisto S., Pekkala M., Sorkio S., Toivanen L., Vahatalo L., Uusitalo U., Ohman T., Bongiorno R., Catteau J., Fraser G., Lloyd M., Crock P., Giles M., Siech K., See D.W., Brown C., Craig M., Johnston A., Bere L.J., Clarson C.L., Jenner M., McManus R., Renato N., Lovell M., Higo D., Kent N., Kwan J., Marshall C., Metzger D., Chanoine J.-P., Stewart L., Thompson D., Edwards A., Lange I., Mercer J., Pacaud D., Josephine H., Schwarz W., Stephure D.K., Boer J., Chatur T., Chick C., Couch B., Demianczuk N., Girgis R., Marks S., Ryan E., Thompson M., Dean H.J., Grant L., Hamelin K., LaForte J., Murphy L., Catte D., Schneider C., Sellers E.A.C., Woo V., Boland A., Clark H.D., Cooper T., Gruslin A., Karovitch A., Keely E., Malcolm J.C., Sauro V., Tawagi G.F., Andrighetti S., Arnold G., Barrett J., Blumer I., Daneman D., Donat D., Ehrlich R., Feig D., Gottesman I., Gysler M., Karkanis S., Kenshole A., Knight B., Lackie E., Lewis V., Martin M.J., Maxwell C., Oliver G., Panchum P., Shilletto N., Simone A., Skidmore M., Turrini T., Wong S., Allen C., Belanger L., Bouchard I., Ferland S., Frenette L., Garrido-Russo M., Leblanc M., Imbeault J., Morin V., Olivier G., Weisnagell J., Costain G., Dornan J., Heath K., MacSween M.-C., McGibbon A., Ramsay C., Sanderson F., Sanderson S., Benabdesselam L., Gonthier M., Huot C., Thibeault M., Laforte D., Legault L., Perron P., Armson A., Canning P., Cummings E.A., Ivanko V., McLeod L., Mokashi A., Scott K., Bridger T., Crane J., Crummell C., Curtis J.C., Dawson C., Joyce C., Newhook L.A., Newman S., Druken E., Begum-Hasan J., Breen A., Houlden R., Woods M., Carrson G., Kelly S., Martel M.J., Penner M., Sankaran K., Hardy-Brown K., King N., White R.A., Park M., Popkin J., Robson L., Coles K., Al Taji E., Cerna M., Cerny M., Francova H., Hainerova I., Kothankova H., Koukalova R., Krakorova V., Mendlova P., Sitova R., Stechova K., Vavrinec J., Vosahlo J., Zlatohlavkova B., Brazdova L., Faksova P., Gregorova D., Kantor L., Malkova K., Venhacova J., Venhacova P., Cipra A., Skvor J., Budejovice C., Tomsikova Z., Botkova-Krauseova H., Mockova A., Paterova P., Gogelova P., Kandrnalova J., Einberg U., Jakovlev U., Posiadlo S., Rannaste E., Raukas R., Riikjarv M.-A., Valla K., Astover V., Kirss A., Retpap J., Taht E., Tillmann V., Vahtra S., Heikkila M., Hirvasniemi M., Luopajarvi K., Johansson S., Kleemola P., Laukkanen E., Parkkola A., Pigg H.-M., Puttonen H., Renlund M., Salonen K., Suomalainen H., Tenkula T., Teramo K., Jarvenpaa A.-L., Hamalainen A.-M., Jussila R., Kiiveri S., Haavisto H., Holopainen S., Kupiainen H., Leeve T., Lumme K., Nironen T., Tenhola S., Tiilikainen T., Keinonen H., Lautala P., Salonen P., Vesanto M., Aspholm A.S., Asunta P., Ikavalko H., Jason E., Jaminki S., Kekki P., Koskinen M., Lehtimaki S., Lahde J., Makela M., Peltoniemi S., Poutiainen L., Ranta K., Salonsaari T., Sarviharju-Tujula S.-L., Selvenius J., Siljander H., Haanpaa P.-L., Holm C., Juutilainen A., Jarvelainen V., Kangaskolkka-Keskilohko A.-M., Laino E., Marjamaki L., Suominen E., Ylitalo S., Hokkanen M., Lounamaa R., Matikainen M., Nuuja A., Paalanen I., Puupponen A.R., Salo-Edwards H., Alanne S., Kultti T., Linjama H., Muhonen K., Vaaraniemi M., Talvitie T., Backman M., Hanhijarvi R., Koivula P., Lindstrom K., Martikainen A., Nurmi P., Bjork A., Huopio H., Komulainen J., Lehtomaki S., Muikku E., Pesola J., Sankilampi U., Arkkola T., Hekkala A., Jurvakainen S., Koivikko M.-L., Kahonen M., Leinonen E., Mykkanen T., Pohjola H., Riikonen K., Niittyvuopio A., Stenius A., Tapanainen P., Veijola R., Alar A., Jovio S., Korpela P., Makinen E., Hietanen L., Kivisto J., Kaar M.-L., Lehtimaki P., Mustila T., Popov E., Saatela S., Taittonen L., Ahtiainen K., Laaksonen N., Luoto M., Viitala J., Virransalo R., Nykanen P., Paajanen S., Parkkinen S., Pyrhonen H., Sarkka T., Aschemeier B., Bektas S., Biester T., Datz N., Deiss D., Fath M., Lupke K., Muller B., Nestoris C., Rothes S., Sadeghian E., Semler K., Arato A., Krikovszky D., Nobilis A., Szenasi J., Benevento D., Anguissola G.B., Biagioni M., Bizzarri C., Cherubini V., Ferrito L., Giordano C., Giorgetti C., Khazrai Y.M., Kyanvash S., Maddaloni E., Napoli A., Piergiovanni F., Pitocco D., Suraci T., Tabacco G., Valente L., Visalli N., Carboni M.B., Cavallo R., Cau V., Isola C., Ledda A., Loddo M., Mannu C., Pettinau M., Pisano S., Porceddu M., Putzu C., Rita A., Peters D., Schierloh U., Bisschoff M., Blonk L., Lappenschaar T., Manai B., Seesink M., Sperling-Conrad M., Verhagen M., Zoethout J.A., Basiak A., Chalas M., Chesiak M., Gramza A., Iwankiewicz J., Sieradzan E., Wikiera B., Ciechanowska M., Dziatkowiak H., Futona B., Gorska A., Glowacka-Wony M., Kaim I., Klich B., Starzyk J., Wolanin M., Tokarska L., Chucherco D., Deja G., Firek-Pedras M., Jarosz-Chobot P., Kalina M., Kutrowska-Adamusiak K., Minkina-Pedras M., Muchaka-Bianga M., Bodalski J., Mlynarski W., Szadkowska A., Cieslak A., Cypryk K., Dziatosz K., Jastzebowska J., Krysiak A., Szymanska U., Wilcznski J., Zawodniak-Szalapska M., Aguay A., Bilbao J.R., Chueca M., Cortazar A., Echarte G., Frutos T.G., Jimenez P., Martul P., Moreno A., Oyarzabal M., Rica I., Salgado Y., Martinez-Larrad M.T., Hawkins F.G., Hernandez R., Herranz L., Pallardo L.F., Deibarra L.S., Fernandez B.H., Luis J.L., Ortiz-Quintana L., Recarte P.P., Arnau D.R., Aronsson L., Boden S., Fredriksson J., Isacsson E., Johansson I., Karlsson E., Lock C., Sandstrom A.-M., Konefal M.S., Andreasson C., Dahlstrom U., Hanas R., Lundqvist K., Windell L., Jansson I., Karlsson A.-K., Lindbladh B., Odenman I., Pettersson C., Sundberg F., Sundqvist M., Aronsson S., Bellman I., Bengtsson A.-B., Lyden G.-B., Nilsson N.-O., Soderblom M., Unt C., Augustsson M., Bengtsson M., Fors H., Helmrich A., Johansson T.O., Andersson A.-C., Boiard-Stomlid A., Hellgren G., Kallsholm H., Lindqvist J., Nilsson M., Nordwall M., Stromstedt C., Ahsberg C., Lindh A., Lindhe C., Samuelsson C., Wiik A., Edenwall H., Ljumgcrantz M., Persson I.-B., Strigard E., Svensson B.-L., Aman J., Breivik G.-E., Detlofsson I.-L., Kroon M., Sarnblad S., Johansson C., Ilvered R., Lundberg A., Akesson K., Beccarelli A., Gadient M., Rappold-Amrein C., Schoenle E., Daftary A., Damagro-Elias M.E., Gilmour C., Klein M.B., Lain C., Salerno D., Smith M.E., Vats K., Pfaff D.J., Malone P., Mansfield P., Munns M., Nickel K., Pompilio K., Siemion W., Taculad R., Van Horn K., Zdanadewic M., Chambliss C., Jones J., Sadler M., Tanner-Blasiar M., Bell C., Camper N., Devaskar S., Devaskar U., Horowitz H., Rogers L., Shannahan R., Silk K., Bermudez Z., Colon R., Frazer T., Martinez-Nieves B., Torres J., Vega J., Chan M., Cook S., Goland R., Greenberg E., Jules N., Montes J., Nelson M., Parra-Valencia Z., Schachner H., Softness B., Kiviniemi M., Suomenin R., Alexander A., Hyrckowian E., Nichol L., Trucco M., Karjalainen E., Louhio T., Sarnesto A., Valtonen E., Davydova B., Helander S., Hamalainen J., Harkonen T., Joutsjoki L., Kararic M., Latva-Koivisto M., Lonn E., Nurmi T., Ollila I., Rinkinen J., Ronkainen M., Tukiainen H., Cederlof A., Kiikeri M., Tsupari S., Cheng R., Bryant K., Chan Y., Maezawa Y., Paltser G., Rasavi R., Tsui H., Winer S., Wu P., Yantha J., University of Zurich, and Knip, Mikael
- Subjects
Male ,Risk ,medicine.medical_specialty ,Casein ,Breastfeeding ,030209 endocrinology & metabolism ,610 Medicine & health ,2700 General Medicine ,Endocrinology and Diabetes ,Disease-Free Survival ,law.invention ,Follow-Up Studie ,Nutrition Policy ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Double-Blind Method ,SDG 3 - Good Health and Well-being ,law ,Internal medicine ,Diabetes mellitus ,medicine ,Humans ,Cumulative incidence ,030212 general & internal medicine ,Child ,Infant Nutritional Physiological Phenomena ,Original Investigation ,2. Zero hunger ,Type 1 diabetes ,business.industry ,Hazard ratio ,Absolute risk reduction ,Infant, Newborn ,Caseins ,General Medicine ,ta3121 ,medicine.disease ,Infant Formula ,3. Good health ,Diabetes Mellitus, Type 1 ,Infant formula ,10036 Medical Clinic ,Endokrinologi och diabetes ,Female ,business ,Human ,Follow-Up Studies - Abstract
IMPORTANCE Early exposure to complex dietary proteins may increase the risk of type 1 diabetes in children with genetic disease susceptibility. There are no intact proteins in extensively hydrolyzed formulas. OBJECTIVE To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of type 1 diabetes in young children. DESIGN, SETTING, AND PARTICIPANTS An international double-blind randomized clinical trial of 2159 infants with human leukocyte antigen-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1081 were randomized to be weaned to the extensively hydrolyzed casein formula and 1078 to a conventional formula. The follow-up of the participants ended on February 28, 2017. INTERVENTIONS The participants received either a casein hydrolysate or a conventional adapted cows milk formula supplemented with 20% of the casein hydrolysate. The minimum duration of study formula exposure was 60 days by 6 to 8 months of age. MAIN OUTCOMES AND MEASURES Primary outcome was type 1 diabetes diagnosed according to World Health Organization criteria. Secondary outcomes included age at diabetes diagnosis and safety (adverse events). RESULTS Among 2159 newborn infants (1021 female [47.3%]) who were randomized, 1744 (80.8%) completed the trial. The participants were observed for a median of 11.5 years (quartile [Q] 1-Q3, 10.2-12.8). The absolute risk of type 1 diabetes was 8.4% among those randomized to the casein hydrolysate (n = 91) vs 7.6% among those randomized to the conventional formula (n = 82) (difference, 0.8%[95% CI, -1.6% to 3.2%]). The hazard ratio for type 1 diabetes adjusted for human leukocyte antigen risk group, duration of breastfeeding, duration of study formula consumption, sex, and region while treating study center as a random effect was 1.1 (95% CI, 0.8 to 1.5; P = .46). The median age at diagnosis of type 1 diabetes was similar in the 2 groups (6.0 years [Q1-Q3, 3.1-8.9] vs 5.8 years [Q1-Q3, 2.6-9.1]; difference, 0.2 years [95% CI, -0.9 to 1.2]). Upper respiratory infections were the most common adverse event reported (frequency, 0.48 events/year in the hydrolysate group and 0.50 events/year in the control group). CONCLUSIONS AND RELEVANCE Among infants at risk for type 1 diabetes, weaning to a hydrolyzed formula compared with a conventional formula did not reduce the cumulative incidence of type 1 diabetes after median follow-up for 11.5 years. These findings do not support a need to revise the dietary recommendations for infants at risk for type 1 diabetes. Funding Agencies|Eunice Kennedy Shriver National Institute of Child Health and Development (NICHD); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health [HD040364, HD042444, HD051997]; Canadian Institutes of Health Research; Commission of the European Communities [QLK1-2002-00372]; European Foundation for the Study of Diabates/JDRF/Novo Nordisk; Academy of Finland (Centre of Excellence in Molecular Systems Immunology and Physiology Research) [250114]; Dutch Diabetes Research Foundation; Finnish Diabetes Research Foundation; JDRF
- Published
- 2018
42. SANS Studies of Polymers in Organic Solvents and Supercritical Fluids in the Poor, Theta, and Good Solvent Domains
- Author
-
Melnichenko, Y. B., primary, Kiran, E., additional, Heath, K., additional, Salaniwal, S., additional, Cochran, H. D., additional, Stamm, M., additional, Van Hook, W. A., additional, and Wignall, G. D., additional
- Published
- 1999
- Full Text
- View/download PDF
43. Ocular findings as predictors of carotid artery occlusive disease: Is carotid imaging justified?
- Author
-
McCullough, Heath K., Reinert, Carol G., Hynan, Linda S., Albiston, Christy L., Inman, Mary H., Boyd, Patty I., Welborn, M. Burress, III, Clagett, G. Patrick, and Modrall, J. Gregory
- Published
- 2004
44. Automated attention flags in chronic disease care planning
- Author
-
Warren, James R., Noone, Joseph T., Smith, Brian J., Ruffin, Richard, Frith, Peter, van der Zwaag, Berend J., Beliakov, Gleb V., Frankel, Heath K., and McElroy, Heather J.
- Subjects
Decision support systems -- Evaluation ,Diseases -- Care and treatment ,Respiratory disease nursing -- Practice ,Health - Abstract
An investigated is conducted into the value of automated decision support in the management of chronic respiratory disease. A comparison is made of the agreements of three respiratory specialists. It is seen that computerised decision support can allow GPs improved access to the intent of guidelines.
- Published
- 2001
45. 333 The First Twenty: The Use of Synthetic Dermal Substitute in Significant Burns; Outcomes and Lessons Learned
- Author
-
Damkat-Thomas, L, primary, Kurmis, R, additional, Heath, K, additional, Schmit, B, additional, Wagstaff, M, additional, and Greenwood, J E, additional
- Published
- 2019
- Full Text
- View/download PDF
46. 326 Early Therapy Experience with NovoSorb™ BTM
- Author
-
Klotz, T, primary, Heath, K, additional, Schmitt, B, additional, Kurmis, R, additional, Wagstaff, M, additional, and Greenwood, J E, additional
- Published
- 2019
- Full Text
- View/download PDF
47. Experiences and attitudes of consultant and nontraining grade anaesthetists to continuing medical education (CME)
- Author
-
Heath, K. J. and Jones, J. G.
- Published
- 1998
48. Supporting special-purpose health care models via adaptive interfaces to the web
- Author
-
Warren, James R., Frankel, Heath K., and Noone, Joseph T.
- Published
- 2002
- Full Text
- View/download PDF
49. The effects of nerve agent pre-treatment with pyridostigmine on the duration of action of suxamethonium
- Author
-
Heath, K. J., Niemiro, L. A.K., Gosden, E. A., and Restall, J.
- Published
- 1996
50. Poliomyelitis in Namibia
- Author
-
Biellik, R J, Lobanov, A, Heath, K, Reichler, M, Tjapepua, V, Allies, T, van Niekerk, A B W, and Schoub, B D
- Published
- 1994
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.